First Bank & Trust decreased its position in Johnson & Johnson (NYSE:JNJ) by 88.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 781 shares of the company’s stock after selling 6,006 shares during the period. First Bank & Trust’s holdings in Johnson & Johnson were worth $103,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of JNJ. Johanson Financial Advisors Inc. bought a new position in Johnson & Johnson in the first quarter worth approximately $1,333,000. Round Table Services LLC raised its stake in Johnson & Johnson by 7.3% in the first quarter. Round Table Services LLC now owns 4,782 shares of the company’s stock worth $596,000 after buying an additional 324 shares in the last quarter. Gemmer Asset Management LLC raised its stake in Johnson & Johnson by 32.5% in the first quarter. Gemmer Asset Management LLC now owns 7,186 shares of the company’s stock worth $895,000 after buying an additional 1,764 shares in the last quarter. Sanders Morris Harris Inc. raised its stake in Johnson & Johnson by 5.3% in the first quarter. Sanders Morris Harris Inc. now owns 7,950 shares of the company’s stock worth $990,000 after buying an additional 400 shares in the last quarter. Finally, Asset Dedication LLC raised its stake in Johnson & Johnson by 1.5% in the first quarter. Asset Dedication LLC now owns 12,093 shares of the company’s stock worth $1,488,000 after buying an additional 174 shares in the last quarter. 65.93% of the stock is owned by institutional investors.
Shares of Johnson & Johnson (NYSE:JNJ) opened at $139.76 on Tuesday. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $144.35. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. The company has a market cap of $374,930.72, a price-to-earnings ratio of 19.55, a price-to-earnings-growth ratio of 2.84 and a beta of 0.82.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same period in the prior year, the company earned $1.68 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. equities research analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.40%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s payout ratio is 58.33%.
JNJ has been the topic of a number of recent analyst reports. UBS AG reaffirmed a “buy” rating and set a $148.00 price target (up from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Goldman Sachs Group, Inc. (The) downgraded Johnson & Johnson from a “neutral” rating to a “sell” rating and upped their price target for the stock from $125.00 to $130.00 in a research report on Wednesday, September 20th. BMO Capital Markets reaffirmed a “buy” rating and set a $145.00 price target on shares of Johnson & Johnson in a research report on Friday, September 1st. Alembic Global Advisors downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Finally, Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $143.70.
ILLEGAL ACTIVITY WARNING: “First Bank & Trust Lowers Position in Johnson & Johnson (JNJ)” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/11/14/first-bank-trust-lowers-position-in-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.